IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---|---|
| Attorney Docket No.: | **RTSP-0240** |
| Inventors: | **Monia and Cowsert** |
| Serial No.: | **Not Yet Assigned** |
| Filing Date: | **Herewith** |
| Examiner: | **Not Yet Assigned** |
| Group Art Unit: | **Not Yet Assigned** |
| Title: | **Antisense Modulation of Liver Glycogen Phosphorylase Expression** |

#2 I.D.S

"Express Mail" Label No. **EV017478055US**
Date of Deposit **December 28, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By _____
Typed Name: Jane Massey Licata, Reg. No. 32,257

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

**(XX)** In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a First Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The fee of $**180.00** as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of $**130.00** as set forth in §1.17(i)(1).

( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

**(XX)** In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. **09/357,071**, filed **July 19, 1999**, in which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

**( )** The relevance of the listed references in a foreign language is as stated in the specification at pages ___.

**(XX)** All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata
Registration No. 32,257

Date: **December 28, 2001**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

| Form PTO-1449 Modified<br><br>List of Patents and Publications Cited by Application (Use several sheets if necessary)<br><br>U.S. Department of Commerce Patent and Trademark Office | Docket No.<br>RTSP-0240 | Serial No.<br>Not Yet Assigned |
|---|---|---|
| | Applicant<br>Monia and Cowsert | |
| | Filing Date<br>Herewith | Group<br>Not Yet Assigned |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---|---|---|
| | AA | Burwinkel *et al.*, *Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI*, Am. J. Hum. Genet., 1998, 62:785-791 |
| | AB | Chang *et al.*, *Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI*, Hum. Mol. Genet., 1998, 7:865-870 |
| | AC | Hoover *et al.*, *Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase*, J. Med. Chem., 1998, 41:2934-2938 |
| | AD | Kasvinsky *et al.*, *Regulation of the dephosphorylation of glycogen phosphorylase a and synthase b by glucose and caffeine in isolated hepatocytes*, Can. J. Biochem., 1981, 59:387-395 |
| | AE | Kasvinsky *et al.*, *The regulation of glycogen phosphorylase alpha by nucleotide derivatives. Kinetic and x-ray crystallographic studies*, J. Biol. Chem., 1978, 253:3343-3351 |
| | AF | Kasvinsky *et al.*, *Synergistic regulation of phosphorylase a by glucose and caffeine*, J. Biol. Chem., 1978, 253:9102-9106 |
| | AG | Keppens *et al.*, *Regulation of glycogen phosphorylase activity in isolated human hepatocytes*, Hepatology, 1993, 17:610-614 |
| | AH | Martin *et al.*, *Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo*, Proc. Natl. Acad. Sci. U. S. A., 1998, 95:1776-1781 |
| | AI | Newgard *et al.*, *The polymorphic locus for glycogen storage disease VI (liver glycogen phosphorylase) maps to chromosome 14*, Am. J. Hum. Genet., 1987, 40:351-364 |
| | AJ | Newgard *et al.*, *The family of glycogen phosphorylases: structure and function*, Crit. Rev. Biochem. Mol. Biol., 1989, 24:69-99 |

| EXAMINER | DATE CONSIDERED |
|---|---|

| Form PTO-1449 Modified<br>List of Patents and Publications Cited by Applicant<br>(Use several sheets if necessary)<br>U.S. Department of Commerce | Docket No.<br>RTSP-0240 | Serial No.<br>Not Yet Assigned |
|---|---|---|
| | Applicant<br>Monia and Cowsert | |
| | Filing Date<br>Herewith | Group<br>Not Yet Assigned |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

| | | |
|---|---|---|
| | AK | Newgard et al., "Sequence analysis of the cDNA encoding human liver glycogen phosphorylase reveals tissue-specific codon usage", *Proc. Natl. Acad. Sci. USA* **1986** 83:8132-8136 |
| | AL | Sprang et al., "Structural changes in glycogen phosphorylase induced by phosphorylation", *Nature* **1988** 336:215-221 |
| | AM | Branch A.D., "A good antisense molecule is hard to find", *TIBS* 23 **1998** 45-50 |
| | AN | Crooke S.T., Basic Principles of Antisense Therapeutics Chapter 1 |
| | AO | Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays", *Nature Biotechnology* **1997** 15:537-541 |
| | AP | Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle", *Chemical Reviews* **1990** 90:4 :543-584 |
| | | |
| | | |
| | | |

| EXAMINER | DATE CONSIDERED |
|---|---|

531 Rec'd PCT 28 DEC 2001



| Form PTO-1449 Modified<br><br>List of Patents and Publications Cited by Applicant<br>(Use several sheets if necessary)<br><br>U.S. Department of Commerce<br>Patent and Trademark Office | Docket No.<br>**RTSP-0240** | Serial No.<br>**Not Yet Assigned** |
|---|---|---|
| | Applicant<br>**Monia and Cowsert** | |
| | Filing Date<br>**Herewith** | Group<br>**Not Yet Assigned** |

**U. S. PATENT DOCUMENTS**

| Examiner | | Document | Date | Name | Class | Subclass |
|---|---|---|---|---|---|---|
| | AA | 6,043,091 | 3-28-00 | Monia et al. | 435 | 375 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initial | | Document No. | Date | Country | Translation YES | NO |
|---|---|---|---|---|---|---|
| | AB | WO 97/09040 | 3-13-97 | PCT | x | |
| | AC | WO 95/24391 | 9-14-95 | PCT | x | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| EXAMINER | DATE CONSIDERED |
|---|---|